- Home
- AWF vs XNCR Comparison
AWF vs XNCR Comparison
Compare AWF & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AWF | XNCR |
|---|---|---|
| Founded | 1993 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.9M | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AWF | XNCR |
|---|---|---|
| Price | $10.21 | $12.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 458.8K | ★ 699.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.57% | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $9.85 | $6.92 |
| 52 Week High | $11.43 | $18.69 |
Technical Indicators
Market Signals| Indicator | AWF | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.37 | 52.47 |
| Support Level | $9.99 | $12.19 |
| Resistance Level | $10.24 | $13.10 |
| Average True Range (ATR) | 0.10 | 0.82 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 4.29 | 56.81 |
Price Performance
Historical ComparisonAbout AWF Alliancebernstein Global High Income Fund
Alliancebernstein Glb High Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its primary investment objective is to seek high current income, and secondarily, capital appreciation. The fund invests in debt securities, including Sovereign Debt Obligations and corporate debt, denominated in non-U.S. currencies as well as in the U.S. Dollar. It may invest without limit in emerging and developed markets and debt securities of U.S. and non-U.S. corporate issuers.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.